Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2323]

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF...

Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours ( Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Treatment management of favourable risk and very favourable risk patients

Dr Guillermo de Velasco and Dr Marco Maruzzo

Treatment management of favourable risk and very favourable risk patients ( Dr Guillermo de Velasco and Dr Marco Maruzzo )

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant...

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic...

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Key insights from head and neck research at ASCO 2025

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Key insights from head and neck research at ASCO 2025 ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

ASCO 2025: Developments in the treatment of soft tissue sarcoma

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA

ASCO 2025: Developments in the treatment of soft tissue sarcoma ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran

Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC ( Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas )

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2...

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )

More from ecancer